Excessive Daytime Sleepiness Clinical Trials

31 clinical trials for Excessive Daytime Sleepiness across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Impact of Bright Light Therapy on Prader-Willi Syndrome — RECRUITING · NA
• Sleep and Stroke Rehabilitation Study — RECRUITING
• A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age — RECRUITING · PHASE1
• Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal — RECRUITING · NA
• SLEEPINESS - a Search for a Biomarker of Excessive Daytime Sleepiness in Severe Obstructive Sleep Apnoea - An Explorative Study — RECRUITING
• A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy — COMPLETED · PHASE3
• Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study — COMPLETED · PHASE4
• A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia — COMPLETED · PHASE3
• A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) — COMPLETED · PHASE3
• Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 — COMPLETED · PHASE2
• Characterization of Children with Complaints of Excessive Daytime Sleepiness — COMPLETED
• BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness — COMPLETED · PHASE2
• A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA) — COMPLETED · PHASE3
• Alternative Epworth Sleepiness Scale ESS-ALT in French — COMPLETED
• A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA — COMPLETED · PHASE3
• Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy — COMPLETED · PHASE2
• Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy — COMPLETED · PHASE3
• Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA — COMPLETED · PHASE3
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness — WITHDRAWN · PHASE3
• Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) — COMPLETED · PHASE3
• Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) — TERMINATED · PHASE2
• BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS — COMPLETED · PHASE3
• BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. — COMPLETED · PHASE3
• A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy — COMPLETED · PHASE2
• Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome — COMPLETED · PHASE3
• Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness — COMPLETED · PHASE3
• Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy — COMPLETED · PHASE3
• Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) — COMPLETED · PHASE2
• Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients — COMPLETED · PHASE2
• Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy — COMPLETED · PHASE3
• Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder — COMPLETED · PHASE2

Refine this search